Latest news with #AtopicDermatitis
Business Insider
4 days ago
- Business
- Business Insider
Zoetis downgraded to Hold from Buy at Stifel
Stifel analyst Jonathan Block downgraded Zoetis (ZTS) to Hold from Buy with a price target of $160, down from $165. The firm contends that the Street's 2026/27 operational revenue growth estimates for Zoetis may 'prove aggressive' as it expects the company's revenue growth rate to decelerate further and compress the stock's multiple or at least prevent a further multiple expansion, the analyst tells investors in a research note. Zoetis has dealt effectively with competition in the past, but this time, competitive inroads may prove more successful, with Stifel's survey identifying strong veterinarian interest in Merck's (MRK) pending Atopic Dermatitis JAK inhibitor and Elanco's (ELAN) CQ – chloroquine – gaining traction, the firm added. Confident Investing Starts Here:
India Today
13-06-2025
- Health
- India Today
Bathing dos and don'ts for babies with sensitive skin
A baby's skin is remarkably delicate, approximately 30% thinner than that of adults, making it more susceptible to moisture loss and irritation. In the summer and monsoon months, factors like heat, humidity and perspiration can further aggravate a baby's delicate skin, but for babies with sensitive skin conditions, these seasonal changes can result in increased rashes and flare-ups. Their skincare regimen needs special care and start by understanding sensitive conditions and why they need extra babies have delicate and sensitive skin, but some are born with or are prone to specific skin conditions such as Atopic Dermatitis (AD), Eczema, Xerosis, and Diaper Dermatitis. We are increasingly seeing a rise in sensitive skin conditions among Indian babies, with the prevalence of AD affecting them at twice the rate of adults globally. Factors like urbanisation, pollution, and climate change, particularly rising temperatures and humidity, have contributed to the growing incidence of conditions like AD. A recent expert consensus from the Indian Academy of Paediatrics (IAP) reports that the prevalence of Atopic Dermatitis in Indian children has increased, ranging between 20% and 39%. Therefore, parents need to adopt science-backed skincare practices to effectively manage these Every day, we meet parents who have many concerns about how to manage these sensitive skin conditions in their babies, especially during bath time. How often should one bathe the baby? Will bathing worsen flare-ups? What cleansers to use? Should one look out for specific ingredients?Here's a comprehensive guide on the dos and don'ts of bathing babies with sensitive skin, emphasizing their comfort, health, and skin integrity. This information is provided by Dr. Karthick Annamalai, MD in Pediatrics, DAA, PGPN, PDFNIC, FAGE, a Consultant Pediatrician, Neonatologist, and specialist in Pediatric Allergy and Asthma at Coimbatore Children's Healthcare in Coimbatore.1. DON'T OVERWASH – KEEP BATH TIME ROUTINE SHORTOverbathing can strip the child's skin of its natural oils, weakening the protective barrier and increasing the risk of dryness, itching, and eczema flare-ups. The Indian Academy of Paediatrics (IAP) recommends that for babies' sensitive skin, the duration of the bath should not exceed 5–10 minutes.[2]They should be bathed in lukewarm water, while avoiding hot baths, as it could further irritate the skin soaps are alkaline and can upset the skin's mildly acidic pH, resulting in further weakening of the stratum corneum. It is recommended to use a soap-free, pH-balanced, fragrance-free, hypoallergenic cleanser. Such products usually have emollient-rich ingredients like glycerine, a humectant that attracts moisture into the skin, providing hydration while carefully stripping sweat, sebum, and environmental pollutants. Lack of harsh surfactants minimises the chances of dryness or irritation post-wash, which is crucial in peak heat It is recommended to use a soap-free, pH-balanced cleanser, preferably oat-based, that's gentle enough for daily use. Avoid harsh soaps or foaming agents that can disrupt the skin's microbiome.2. POST BATH, ALWAYS APPLY MOISTURISERS TO LOCK IN MOISTUREDuring bathing, the cleanser can remove the skin's natural lipids. Applying a soothing moisturiser immediately after the bath, while the skin is still slightly damp, helps seal in moisture and reinforces the skin barrier. The IAP guidelines support the use of emollients containing ceramides, lipids, n-palmitoyl ethanolamine, and natural colloidal Skip moisturising even if the skin appears fine. Preventive hydration is key to moisturising and is also important to reduce flare-ups in babies with sensitive skin conditions or those at high risk for the same.3. DO CHOOSE INGREDIENTS RICH IN COLLOIDAL OATMEALSeasonal changes with extreme summer and monsoon-related humidity bring challenges like heat, sweat, and increased sensitivity. For babies with sensitive skin, soothing ingredients such as colloidal oats can provide relief, and these natural agents help soften babies' skin and soothe inflammation, reduce itchiness and irritation, and protect the skin against environmental stressors. Further, Oat Extract works with other ingredients to moisturise the baby's Look for products that are hypoallergenic, fragrance-free, and free from harsh chemicals like parabens, sulphates, and Use adult skincare products on babies. Their formulations are not tailored for infant skin and could do more harm than a baby with sensitive skin requires a balanced approach, gentle cleansing, thorough moisturising, and consistent protection. By keeping baths short, using appropriate cleansers and emollients, and ensuring post-bath hydration, parents can help their babies maintain healthy, comfortable skin even during the harsh weather months. Mindful choices in skincare routines can significantly reduce the impact of sensitive skin conditions, promoting a happier and healthier life.
Yahoo
22-05-2025
- Health
- Yahoo
Atopic Dermatitis 68-Market Drug Forecast and Market Analysis to 2033
Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis: 68-Market Drug Forecast and Market Analysis" report has been added to publication is an expanded version of the Excel model containing the patient-based forecast (PBF) sales for atopic dermatitis, covered in the analyst's report "Atopic Dermatitis: Seven-Market Drug Forecast and Market Analysis", published in March 2025. In addition to PBF sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 61 geographical markets (61M), totaling 68 markets (68M). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from the analyst's World Markets Healthcare and POLI Price Intelligence databases. For more information on the methodology and assumptions used in the analyst's forecast extrapolations, please refer to the Methodology and Assumptions tabs in the Excel model for this analyst estimated that the atopic dermatitis market was $12.0 billion across the 68MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $28.6 billion, increasing at a compound annual growth rate (CAGR) of 9.1%. This strong growth will be fuelled by driven by the launch of 17 late-stage pipeline agents in the 7MM, increase in treatment options for all age groups and severities, high diagnosed prevalence of atopic dermatitis and high treatment rates across all markets in the 7MM, and novel mechanisms of action anticipated to enter the atopic dermatitis market over the forecast Overview of AD - including epidemiology, disease etiology and management.? Topline AD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs in the 7MM.? Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.? Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.? Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers and barriers. Reasons to Buy Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.? Develop business strategies by understanding the trends shaping and driving the atopic dermatitis (AD) therapeutics market.? Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seven-market AD market in the future.? Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.? Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.? Track drug sales in the seven-market AD therapeutics market from 2023-2033.? Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.? Key Topics Covered: 1 Executive Summary1.1 Overview1.2 68M summary statistics1.3 Key 7MM events driving the 68M forecast extrapolation2 Appendix2.1 Abbreviations2.2 Methodology2.2.1 Patient-based forecast methodology2.2.2 68M forecast extrapolation methodology2.3 Primary research - key opinion leaders interviewed for this report2.4 Primary research - prescriber survey2.5 About the authors2.5.1 Analyst2.5.2 Managing analyst2.5.3 Therapy area directors2.5.4 Epidemiologist2.5.5 Epidemiology reviewers2.5.6 Vice President of Disease Intelligence and Epidemiology2.5.7 Global Head of Pharma Research, Analysis, and Competitive Intelligence3 About the AnalystCompanies Featured AbbVie Aclaris Therapeutics Acrotech Biopharma Amgen AOBiome Therapeutics Arcutis Biotherapeutics Astria Therapeutics Dermavant Eli Lilly Galderma GlaxoSmithKline Incyte Japan Tobacco Kyowa Kirin LEO Pharma Maruho Nektar Otsuka Pfizer Regeneron Sanofi Torii Pharmaceutical Union Therapeutics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
19-05-2025
- Business
- Yahoo
Atopic Dermatitis (Atopic Eczema) Global Clinical Trials Review 2025
This comprehensive report offers an overview of clinical trials, featuring data by region, country, phase, and sponsor type. Unlock competitive advantages with detailed analysis of ongoing trials and enrollment trends. Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2025" has been added to offering. The report delivers a comprehensive insight into the current landscape of clinical trials focused on Atopic Dermatitis (Atopic Eczema) worldwide. Leveraging data from the proprietary Pharma - Clinical trials database, the report encapsulates a broad spectrum of clinical trial information, presenting crucial statistics such as trial numbers and average enrollment across leading countries globally. This robust database aggregates information from over 80 diverse sources including clinical trial registries, conferences, journals, and news outlets, ensuring a meticulously updated repository of data. The report's extensive coverage includes detailed insights broken down by region and country (G7 & E7), trial phase, trial status, endpoints, and sponsor type. It highlights active trials and the significant drugs that are currently under investigation, aligning strategic interests with ongoing developments in the field of Atopic Dermatitis (Atopic Eczema). Benefits of engaging with this report extend to enhancing decision-making capabilities, crafting strategic responses, and securing a competitive market advantage. Although some sections may be adapted based on data availability and relevance, the offering continues to provide an indispensable tool for stakeholders aiming to navigate the clinical trials landscape effectively. Scope: Presents a snapshot of the global clinical trials environment. Delivers top-level data related to clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status. Evaluates leading companies and lists trials (title, phase, and status) associated with them. Documents all unaccomplished trials (terminated, suspended, and withdrawn), including reasons for their cessation. Analyzes enrollment trends over the past five years. Reports on the latest relevant news from the last three months. Key Topics Covered: Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by E7 Countries Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Clinical Trials by Sponsor Type Latest Clinical Trials News on Atopic Dermatitis (Atopic Eczema) Clinical Trial Profile Snapshots A selection of companies mentioned in this report includes, but is not limited to: Pfizer Inc Novartis AG Sanofi Regeneron Pharmaceuticals Inc LEO Foundation Eli Lilly and Co AbbVie Inc Johnson & Johnson Innovaderm Research Inc Thermo Fisher Scientific Inc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Time of India
02-05-2025
- Health
- Time of India
New study finds tofacitinib effective and affordable for refractory atopic dermatitis
New Delhi: New Delhi: Tofacitinib , a Janus kinase (JAK) inhibitor drug, used either as a standalone treatment or alongside other drugs to address moderate to severe cases of rheumatoid arthritis and ankylosing spondylitis, demonstrates effectiveness in managing refractory atopic dermatitis (AD). Tired of too many ads? go ad free now This was revealed in a study published in the Indian Dermatology online journal. Atopic dermatitis (AD) presents as a long-term, recurring inflammatory disorder of the skin, and its characteristic itching significantly affects patients' daily living standards. The research was conducted at the department of dermatology, venereology and leprosy in Atal Bihari Vajpayee Institute of Medical Sciences and Research Institute and Dr Ram Manohar Lohia Hospital. The results established that people who previously showed no response to standard systemic treatments, including oral corticosteroids, cyclosporine and azathioprine, exhibited significant clinical improvement when administered tofacitinib exclusively. The progress was evaluated through decreased Scoring Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI), and Numerical Rating Scale (NRS) measurements at 4-week and 8-week intervals. The principal investigator of the study and dermatologist at RML Hospital, professor Kabir Sardana, explained that their main goal was to evaluate how well tofacitinib worked and its side effects in patients with difficult-to-treat moderate-to-severe AD. Additionally, they aimed to analyse the treatment costs between tofacitinib and dupilumab (approved by the Central Drugs Standard Control Organisation, India) for moderate and severe AD cases. Tired of too many ads? go ad free now The research indicated an average disease duration of three years. Patients displayed moderate to severe pruritus, excoriations, erythema, oozing and crusting. All participants had previously experienced treatment failure or intolerance to systemic therapy; 50% of patients also had other atopic conditions and bronchial asthma. The researchers continued treatment with topical corticosteroids, moisturiser and topical calcineurin inhibitors alongside tofacitinib. Improvements were observed in pruritus, sleep quality, affected body surface area, erythema, excoriation, papulation/edema and lichenification, with notable severity score reductions at four weeks and eight weeks of therapy. Dr Sardana said that EASI 90 was attained by 66% of patients within 8 weeks, with one patient experiencing treatment failure. Patients achieved complete or near-complete disease resolution in an average of 6.1 weeks (ranging from 3-8 weeks). Disease recurrence was observed in 36.3% of patients. Adverse reactions occurred in 41.6% of patients, including herpes zoster, dyslipidemia, anaemia, impetigo, and thrombocytosis. The financial comparison revealed that dupilumab (a monoclonal antibody used to treat various allergic conditions, including atopic dermatitis, asthma, and nasal polyps) therapy costs 122 times more than tofacitinib treatment over an 8-week period.
